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Objectives This pilot prospective observational study aimed to evaluate the maternal and fetal outcomes of pregnancies
under low-dose oral anticoagulation therapy after aortic mechanical replacement.
Background Need for valve replacement is still an issue for young women with native valve disease who are planning on fu-
ture pregnancy. Choice of replacement device is a challenging clinical task.
Methods A comprehensive pre-operative counseling protocol to guide choice of replacement device was developed. The
pre-operative anticoagulation trial to determine the warfarin daily dosage needed to reach target international
normalized ratio (INR) represented the main stem of such protocol. Pregnancies on low-dose anticoagulation
therapy (target INR: 1.5 to 2.5) were allowed in a highly selected subset of mechanical aortic valve recipients.
Results Twenty-two patients of 40 originally referred for native valve disease surgery requiring valve replacement, safely
underwent the pre-operative anticoagulation challenge. No maternal or fetal complications were detected in 16
pregnancies under low oral anticoagulation. Patterns of warfarin daily dosage and induced INRs were character-
ized during pregnancy.
Conclusions In this small sample observational study, a pre-operative anticoagulation therapy trial helped young women
scheduled for valve replacement to acquire complete information as to the choice of prosthetic device. In
selected third-generation mechanical aortic prosthesis recipients, low-dose anticoagulation therapy seems
safe and feasible for both mother and fetus. Further studies are needed to validate this approach. (J Am Coll
Cardiol 2012;59:1110–5) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.899Young women with native valve disease planning on preg-
nancy should undergo a thorough risk assessment to decide
whether an intervention is necessary before pregnancy and
eventually to define its timing and the type of surgical
therapy (1,2). When native valve stenosis needs pre-
pregnancy intervention, there is a consensus that mitral
balloon valvuloplasty is the best option for mitral stenosis,
whereas choice of a prosthetic valve for aortic disease is still
highly debated (2–4). Pregnancy in women with a biopros-
thesis is associated with early and late structural valve
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accepted October 31, 2011.deterioration, implying high reoperation rate. Pregnancy
with a mechanical valve has a high maternal complication
rate, including valve thrombosis and death. Coumarin
derivatives are relatively safe for the mother, with a lower
incidence of valve thrombosis than unfractionated heparin
(UFH) and low-molecular-weight heparin (LMWH), but
carry the risk of embryopathy (5,6).
See page 1116
Less thrombogenic materials and an improved valve and
hinge design in modern bileaflet prostheses have reduced
the propensity for thrombus formation and the need for
aggressive anticoagulation therapy. As for nonpregnant
last-generation prosthetic heart valve patients, low-dose
anticoagulation therapy has been well recognized as 1 of the
possible means to improve quality of anticoagulant prophy-
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coagulable state, the feasibility of low-dose anticoagulation
therapy in the peculiar setting of the heart valve prosthesis
patient management during pregnancy is still undemon-
strated. Since 2000, after our original findings suggesting a
probable dose-dependency of warfarin embryopathy (5,9), a
dedicated multidisciplinary program of pre-operative coun-
seling for women referred for valve surgery who were
contemplating a future pregnancy has been adopted in our
department. A multistage protocol for the choice of pros-
thetic valve type and for management of anticoagulation
therapy during pregnancy has been developed. The aim of
this paper is to report maternal and fetal outcomes of
women undergoing pregnancies after mechanical aortic
valve replacement under low-dose anticoagulation therapy.
Methods
Algorithm for the choice of valve prosthesis. Patients
with aortic disease not suitable for a valve repair procedure
underwent an informative counseling on the choice of valve
substitute and inherent drawbacks, both absolute (need for
anticoagulation therapy versus risk of reoperation) and
related to pregnancy (including reduced durability of bio-
logical prostheses and fetal toxicity of oral anticoagulants for
mechanical devices). Information was given about the risks
of maternal and perinatal morbidity and mortality, and the
risks and benefits of each anticoagulant treatment option.
Such counseling included also the advice that, theoretically,
the safest option was to avoid pregnancy after surgery. To
help in this decision process, patients, after written in-
formed consent and a negative pregnancy test, underwent a
pre-operative 3-month trial of anticoagulation therapy to
evaluate the dose of warfarin needed to achieve the target
international normalized ratio (INR). Since 2000, for se-
lected patients after mechanical aortic valve replacement
(negative anamnesis for thromboembolic events, normal left
ventricular ejection fraction, left atrium diameter 47 mm,
and sinus rhythm), it is our practice to prescribe an INR
between 1.5 and 2.5, as described in the prospective trial by
Torella et al. (8). Target INR for mitral valve replacement
was 2.5 to 3.5. Young women achieving this target INR
with a warfarin daily dose5 mg were preferentially offered
a third-generation mechanical device; however, in case of
aortic prostheses, they were informed about the maternal
hazard related to the use of a low-dose oral anticoagulation
regimen during a hypercoagulable condition. Patients need-
ing higher dosage were preferentially offered a bioprosthesis
or, as a second choice, a mechanical device contingent with
the advice that in both cases poor maternal and/or fetal
outcomes were likely in case of a pregnancy.
Management of anticoagulation therapy during pregnancy.
Women were advised to contact the outpatient clinic as
soon as they missed a period, and to perform pregnancy tests
every 3 days until positive or until menstruation. Upon
confirmation of pregnancy, each pregnant woman com-pleted written informed consent,
whereby she chose 1 of the following
treatment options: 1) heparin (either
UFH or LMWH) during the first
trimester, followed by oral anticoag-
ulation therapy up to the 36th
week, with subsequent replace-
ment by heparin until delivery;
2) oral anticoagulation therapy
throughout pregnancy, until the
36th week, followed by heparin until delivery (either UFH or
LMWH); and 3) the Cotrufo protocol. As previously de-
scribed (5,9), such a protocol, named after its original
developer (Maurizio Cotrufo), was based on sodium warfa-
rin administration throughout all pregnancy; the INR was
estimated on a weekly basis at our outpatient clinic and
recorded along with prescribed warfarin doses. Women with
mechanical aortic valve replacements underwent low-dose
anticoagulation therapy, as described in the preceding text.
Echocardiographic follow-up was performed monthly to
evaluate cardiac and prosthetic function. Patients were
followed up by cardiologists and obstetricians at monthly
intervals until the 37th week of gestation, when they were
electively hospitalized until delivery. Cesarean delivery was
scheduled before the end of the 37th gestational week.
Cesarean section is indicated because of the risk of intra-
cranial bleeding in the anticoagulated baby with vaginal
delivery. Warfarin therapy was discontinued at least 2 days
before surgery and restarted 1 day after surgery. During this
perioperative period, heparin was not routinely adminis-
tered, as collegially considered not necessary for a warfarin
discontinuation of just 3 days, and INRs were checked daily.
For patients presenting no or sluggish increase of INR after
post-partum warfarin resumption, LMWH was added until
the target INR was reached. The whole management
algorithm described here complied with the principles of the
Helsinki Declaration and received ethical approval from the
local ethics committee.
Aim of the study and outcomes definitions. This study
aimed to assess: 1) the results of a multistage counseling
protocol for young women needing valve surgery; and 2) the
rate of maternal thrombotic and hemorrhagic complications
and pregnancy outcomes in women with third-generation
mechanical aortic prostheses who received low-dose oral
anticoagulation treatment with sodium warfarin throughout
all pregnancy. Definition of maternal thrombotic and hem-
orrhagic complications followed current guidelines. Poor
pregnancy outcome was defined as the occurrence of spon-
taneous abortion, stillbirth, or congenital birth defect. Ul-
trasound evaluations of the fetus were done at the third,
fifth, and eighth months. Neonates underwent clinical
examination soon after birth and at 4 and 12 months to
ascertain or exclude the diagnosis of warfarin embryopathy.
All eventual miscarriages and stillbirths were to be clinically
evaluated by neonatologists; indication for a pathology
Abbreviations
and Acronyms
INR  international
normalized ratio
LMWH  low-molecular-
weight heparin
UFH  unfractionated
heparinexamination was left to a case by case decision.
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Pregnancies Under Low Oral Anticoagulation March 20, 2012:1110–5Statistical analysis. Data are expressed as mean  SD for
continuous variables and as percentages for categorical
variables. The Wilcoxon matched pairs signed-rank test (for
the INR variable) or the paired Student t test (for the dose
variable) were used to compare the warfarin daily dose
needed to achieve the target INR during pregnancy to that
needed during the pre-operative anticoagulation trial as well
as mean pre-operative INR to intrapregnancy outcomes.
Statistical significance was set at 0.05. All analyses were
performed with SPSS version 13.0 (SPSS, Inc., Chicago,
Illinois).
Results
Patient population. Between January 2000 and December
010, 40 young women were referred for treatment of
alvular heart disease: 5 required balloon mitral valvulo-
lasty, 9 underwent mitral valve repair, 2 had mitral valve
eplacement, 4 had aortic valve repair, and 20 needed aortic
alve replacement. Women judged suitable for heart valve
eplacement did not experience any complication while
ndergoing the planned anticoagulation trial. Those af-
ected by mitral valve disease reached target INR with
arfarin daily doses 5 mg and decided to be implanted
with a bioprosthesis. Between patients needing aortic valve
replacement, 17 achieved a target INR with a warfarin daily
dose 5 mg and 3 with a daily dose 5 mg. All 17 women
achieving target INR with low-dose warfarin opted for a
Figure 1 Flowchart of Therapeutic Options for Young Women
Patients (pts) unsuitable for valve repair underwent a pre-operative anticoagulation
tional normalized ratio (INR). Results of this anticoagulation test helped patients i
ferred mechanical prostheses.mechanical replacement. Of patients needing higher warfa-
rin daily dose, 1 requested a bioprosthesis and 2 requested a
mechanical device. Choice of a mechanical replacement by
these 2 patients had the following motivation: intention of
the one to undergo a future pregnancy on LMWH regimen,
and the decision by the other to avoid pregnancy and opt for
an international child adoption. Figure 1 reports the man-
agement algorithm of the whole subset of patients referred
for native valve disease.
Pregnancies with a prosthesis. There were 20 pregnancies
after valve replacement surgery. Three patients with a biopros-
thesis (2 mitral, 1 aortic) had 3 healthy fetuses, and none of
them experienced structural valve degeneration so far (mean
follow-up 59 months, minimum 36 months and maximum 84
months). Seventeen patients with a mechanical aortic valve had
17 healthy babies. One pregnancy, as per patient preference,
was carried out under LMWH and was complicated by valve
thrombosis at the 11th week. The patient had been compliant
with medication, and LMWH dose was adjusted to achieve
peak anti-Xa levels of 0.7 to 1.2 U/ml 4 h post-dose, with
anti-Xa levels checked weekly. The patient underwent success-
ful emergency reoperation at our department, the fetus survived
the procedure, and the pregnancy was successfully concluded
under warfarin therapy. Sixteen pregnancies were conducted
according to the Cotrufo protocol with low-dose anticoagula-
tion therapy.
o find out the warfarin dosage needed to achieve postoperative target interna-
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replacement under low dose anticoagulation therapy.
Aortic valve replacement in this subset was always per-
formed with a St. Jude prosthesis. Mean age at pregnancy
was 26.9  3.4 years (range 22 to 36 years). No maternal
thromboembolic or hemorrhagic complications were ob-
served. There were 16 full-term healthy babies. Mean dose
of warfarin during pre-operative anticoagulation test was
4.1  0.7 mg to maintain a mean INR of 2.2  0.5 IU
median 2.05 IU; interquartile range: 2.0 to 2.2 IU). Mean
arfarin dosage during pregnancy was 4.1 0.4 to maintain
mean INR 1.9  0.3 (median 1.9; interquartile range: 1.8
o 2.0). The difference between pre-pregnancy and in-
rapregnancy mean doses of warfarin was 0.1  0.7 (95%
onfidence interval:0.3 to 0.5; p 0.63). In particular, on
verage, 7 patients took a lower dose, 7 a higher dose, and
the same. The difference between pre-pregnancy and
ntrapregnancy mean INR was 0.26  0.25 (95% confi-
ence interval: 0.12 to 0.4; p  0.001). Thirteen
atients had a mean INR lower than that measured before
regnancy, whereas 3 had the same. Oral anticoagulation
anagement in this closely followed study population was
f high quality; 90.2% of a total of 592 INR measurements
ere inside the therapeutic corridor. Adherence to the
nticoagulation protocol during pregnancy is reported in
igure 2. Mean INR after the 2-day period of pre-partum
ithdrawal of warfarin was 1.39 (median 1.4; interquartile
ange: 1.3 to 1.4).
iscussion
he main findings of the present observational study are
hese: 1) multistage counseling may help in the choice of
alve substitute and subsequent management of pregnancy;
Figure 2 Adherence to Anticoagulation Therapy During Pregnan
Boxes represent interquartile range for international normalized ratio (INR), blackand 2) low-dose anticoagulation therapy under strict sur-
veillance appears feasible and safe in highly selected patients
with third-generation aortic mechanical devices. Consistent
with the literature and despite advances in valve repair
procedures, valve replacement surgery, in our tertiary care,
university-affiliated cardiac surgery center, was needed in
55% of young women of childbearing age (22 of 40 patients)
with the highest proportion in those affected by aortic
disease (1–4). Need for multidisciplinary counseling in this
setting was authoritatively underlined by Hanania in 2002
(10). In a clinical situation implying tremendous ethical
issues and several medicolegal drawbacks, physicians must
intervene in the discussion and break the syllogism of the
long-lasting equation that “heparin protects the fetus and
aggravates maternal risk, while oral anticoagulants protect
the mother and aggravate fetal risk.”
In the real world, such counseling has to face both the
limited follow-up data and the lack of consensus documents.
Indeed, guidelines on the antithrombotic therapy in patients
with mechanical heart valve replacements by the American
College of Cardiology/American Heart Association and by
the European Society of Cardiology disagree on many
fundamental issues, including the risk categorization of
different mechanical prostheses and the management of
anticoagulation therapy during pregnancy (11,12). Such
discrepancies, together with the limited experience of most
of cardiac surgery centers, has led to under-care of patients.
In an impressive study by Shannon et al. (13), the antico-
agulant management of pregnancy after heart valve replace-
ment in the United Kingdom between 1986 and 2002 was
reviewed. The study results illustrated the diverse and
uncertain manners in which heart valve recipients were
managed during pregnancy (13).
presents mean INR values, whiskers represent 95% confidence interval INR.cy
line re
1114 De Santo et al. JACC Vol. 59, No. 12, 2012
Pregnancies Under Low Oral Anticoagulation March 20, 2012:1110–5At our department, the multistage counseling initially
devoted to patients who had already undergone a valve
replacement and wanted to have pregnancies has been lately
applied to women referred for surgical treatment (9). Patient
information incorporated both the institutional experience
and up-to-date literature review. Choice of prosthesis was
originally aided by a pre-operative anticoagulation test that
aimed to give hints on future warfarin dosage. Despite
inherent challenges and limitations, all patients facing the
need for replacement surgery promptly consented to this
pre-operative evaluation. Despite aiming at a low-intensity
anticoagulation target, in this pilot sample, oral anticoagu-
lation therapy of 5 mg per day was feasible only in 17 of
20 patients needing aortic replacement and, so far, in none
of those needing mitral replacement surgery. Subsequent
patient choice reflected the patient’s preference as well as
completeness of informative counseling (i.e., avoidance of
pregnancy, pregnancy after bioprosthesis implantation,
pregnancy under LMWH or oral anticoagulation therapy)
and equidistance of counselors.
Coming to the evaluation of pregnancy outcomes, just a
few words may be said on usage of bioprostheses and
bridging anticoagulation therapy with LMWH. Patients
undergoing pregnancies after tissue replacement did not
experience structural valve deterioration and entered a close
echocardiographic follow-up of prosthesis function in the
long term. Absence of structural deterioration may be quite
the reflection of short absolute length of follow-up. As to
the inherent merits of LMWH anticoagulation therapy, no
conclusion may be drawn from a single case experience, but
the observation is that the outcome of such a case is
consistent with those recently reported by others (14,15).
Recent publications have differed in their recommendations
with regard to anti-Xa levels and with target post-dose
levels of 0.7 to 1.2 IU/ml or peak anti-Xa levels of 1.0
IU/ml. By contrast, Elkayam and Bitar (3) recommended
target pre-dose trough levels of 0.6 IU/ml and 0.7 IU/ml
and biweekly monitoring to enhance anticoagulation effi-
ciency. Even apparently insignificant divergences from this
latter protocol (i.e., pre-dose anti-Xa level of 0.4 to 0.7
IU/ml and peak dose of 0.7 to 1.2 IU/ml with monthly
monitoring), have led to suboptimal maternal outcomes
(enoxaparin-related maternal thromboembolism: 10.6%,
95% confidence interval: 4.3% to 22.6%) in recent case series
(16). Similarly, it cannot be excluded that in the single case
of LMWH use in the present series, additional monitoring
of trough levels, beside peak levels, of anti-Xa could have
possibly avoided the thrombotic complication observed
(17,18). Physicians preferring LMWH administration to
pregnant patients with mechanical heart valves commit
themselves to the very delicate task of ensuring absolute
adherence to the best evidence-derived protocols.
As far as the rationale for low anticoagulation after aortic
mechanical replacement is concerned, since the pioneering
experience by Saour et al. (19), for more than a decade
several follow-up series have reported that less intensive oralanticoagulation therapy than previously recommended re-
sults in a lower incidence of bleeding complications without
a significant increase of thromboembolic events. More
recently, several large-scale, multicenter, randomized, pro-
spective studies have validated a policy of low or even very
low intensity anticoagulation therapy for patients with
mechanical heart valves (8,20–22).
Ours is the first report on outcomes of very low antico-
agulation therapy during pregnancy with a mechanical
aortic prosthesis. The excellent results of this small sample
of highly selected, closely monitored pregnant women may
certainly give rise to several questions, above all, questions
about: 1) reliability of pre-operative anticoagulation chal-
lenge; and 2) and the inherent merits of low-dose antico-
agulation therapy, low warfarin daily dose, and quality of
anticoagulation therapy management. As to the first, vali-
dation of the ability of pre-operative anticoagulation pattern
to predict dose-response effect of warfarin during pregnancy
is beyond the scope of this observational study. Neverthe-
less, taking into account sample size, as shown in Figure 1,
managing anticoagulation within target INR without ex-
ceeding 5 mg warfarin per day was feasible in all patients
who opted for receiving aortic valve replacement. As to the
second, absence of maternal thromboembolic events cer-
tainly depends on a composite of patient profile, prosthesis
characteristics, and close anticoagulation surveillance; simi-
larly, lack of fetal complications results from the additive
effects of low target INR and low warfarin daily dose.
Study limitations. Several study limitations deserve con-
siderations for a thorough data interpretation. First, the
magnitude of the study sample may raise concerns. Overall
patient population is certainly limited, and the subgroup
undergoing low-dose anticoagulation therapy is even
smaller. Nevertheless, both because available data in litera-
ture are few and somewhat contradictory and because
inclusion criteria and management protocol of the present
study were stringent, even the analysis of a small series may
add importantly to the knowledge of the topic. Second, dose
dependency of warfarin fetal complications was originally
suggested by our group and later supported by reports from
others (23,24) published in lower visibility journals. Overall,
the evidence of the safety of low-dose warfarin is currently
based on low numbers: the present study itself, as none of
the patients requiring 5 mg warfarin daily chose to
become pregnant on warfarin, could not provide any further
support to that theory. Conversely, it must be acknowledged
that Sadler et al. (25) showed miscarriage in 7 of 11 women
whose maximum dose of warfarin was 5 mg compared to
5 of 11 women who received 5 mg. Therefore, although
the low-dose warfarin proposal was incorporated in the
current European guidelines (12), the level of clinical
evidence of such advice is low, as well as that assigned to the
other available advices, because of the generalized lack of
definitive data. Third, when applying our protocol, the
inherent risks of a cesarean delivery at the 37th week should
be considered, including, in addition to neonatal prematu-
22
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pain, infections, respiratory complications, damage to pelvic
organs, and potential unfavorable effects on future repro-
ductive health (26,27). Finally, although no prosthetic
degeneration was observed after pregnancy, the shortness of
follow-up of our patients receiving bioprostheses hampers a
sound conclusion on the safety of this alternative option.
For all the aforementioned limitations, the present pilot
study results should be viewed with due caution, and they
surely need verification in a larger study sample.
Conclusions
Comprehensive pre-operative counseling is mandatory for
young women with valvular heart disease planning on future
pregnancy as valve replacement surgery is still an issue for
this subset. Availability of a broad state-of-the-art surgical
armamentarium, advanced expertise of anticoagulation ther-
apy protocols, and close long-term follow-up capabilities are
prerequisites for counseling pregnancy management and
ensuring good late maternal outcomes. In this pilot obser-
vational study, the required dose of warfarin emerging from
a pre-operative anticoagulation trial was added to the factors
helping young women scheduled for valve replacement to
receive individualized information guiding the choice of
prosthetic device. Obviously, it should not be the only factor
to consider, inasmuch as women needing5 mg daily could
choose to have pregnancies with mechanical valves as well
and to receive heparin-based protocols instead of oral
anticoagulation therapy. Alternatively, considering the re-
cent spreading of percutaneous techniques of valve implan-
tation, a woman could choose to have a bioprosthesis and to
undergo valve-in-valve implantation in case of pregnancy-
related bioprosthetic degeneration.
For a highly selected and relatively small number of
third-generation mechanical aortic valve recipients, low-
dose anticoagulation therapy was associated with no mater-
nal or fetal complications. Further studies are needed to
validate this approach.
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